Rocket Healthcare announced on the 7th that it had submitted a securities report to the Financial Services Commission. Afterwards, it plans to finalize the offering price through demand forecasting for institutional investors and proceed with general subscription. The lead underwriter is SK Securities.
Rocket Healthcare is a company that develops and supplies cutting-edge regenerative medical solutions for diabetic foot, skin regeneration, cartilage regeneration, and kidney regeneration based on its 'AI hyper-personalized customized organ regeneration platform' technology. It uses artificial intelligence software and medical 3D bio-printers to produce necessary patches or organs for patients to help with treatment.
In particular, for diabetic foot, an incurable disease, Rocket Healthcare has proven safety and efficacy by conducting clinical trials in India, Korea, the United States, Turkey, and other countries with many diabetic foot patients by utilizing skin regeneration platform technology.
Based on these technologies and clinical results, Rocket Healthcare has obtained medical device registration and approval in each country, including the US FDA and the EU CE MDR, and has signed sales contracts in 44 countries and is exporting to the US, Europe, South America, Asia, the Middle East, and Africa.
The increase in sales targeting the global market is continuing in annual performance. Rocket Healthcare recorded sales of KRW 9.2 billion on a consolidated basis in 2022, and increased to KRW 12.4 billion in 2023. In addition, it is securing soundness by reducing losses every year. Cumulative sales for the third quarter of 2024 on a consolidated basis were KRW 9.4 billion.
“This listing will mark an important turning point for us to expand our AI-based hyper-personalized customized organ regeneration platform into the global market,” said Yoo Seok-hwan, CEO of Rocket Healthcare. “We will further strengthen our position in the global medical market, contribute to improving the quality of life of patients with incurable diseases based on innovative regenerative medicine technology, and achieve continuous growth as a ‘Global First Mover.’”
- See more related articles
You must be logged in to post a comment.